Replies to post #86608 on $heff's $tation of $tocks & $olid DD

[BiotechValues]

$ZGNX- seems like a no-brainer to me when deal is worth $100M more than the market cap of company and they have two new drugs in development. The market for the Dravat's syndrome drug is tiny, but Relday = huge future market opportunity (if approved).

[Bob Stocks]

ZGNX people concentrated on the sale of Zohydro...but their unique injectable Relday will report phase 2 data in Q3 are is way more valuable....plenty of cash....Relday would be an over 1 billion dollar drug.